Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY)
(Delayed Data from OTC)
$25.75 USD
-0.44 (-1.68%)
Updated Oct 14, 2025 03:59 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Daiichi Sankyo Co., Ltd. - Sponsored ADR has a PEG ratio of 1.48 compared to the Medical - Drugs industry's PEG ratio of 1.33.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DSNKY 25.75 -0.44(-1.68%)
Will DSNKY be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for DSNKY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DSNKY
DSNKY vs. ZTS: Which Stock Is the Better Value Option?
TAK or DSNKY: Which Is the Better Value Stock Right Now?
DSNKY: What are Zacks experts saying now?
Zacks Private Portfolio Services
TAK vs. DSNKY: Which Stock Is the Better Value Option?
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
TAK or DSNKY: Which Is the Better Value Stock Right Now?
Other News for DSNKY
Daiichi Sankyo Company, Limited (DSKYF) Q2 2024 Earnings Call Transcript
AstraZeneca, Daiichi win FDA review for Enhertu label expansion
DESTINY-Breast05 phase 3 trial delivers positive topline results
Trump’s 100% drug tariffs send pharma stocks lower
Daiichi Sankyo Company, Limited (DSNKY) Discusses On WCLC 2025 Highlights (Transcript)